NURS 663 EXAM 2
NURS 663 EXAM 2 Questions and
Answers 2025
Anorexia Nervosa
"RID" - Ans ✅-R: Restriction of intake leading to significantly low body weight
I: Intense fear of weight gain
D: Disturbance in perception of one's weight or body image
When Anorexia Nervosa is Diagnosed - Ans ✅-When a person's weighs at least 15%
less than their normal/idea body weight
Anorexia Nervosa
Subtype Restricting Type - Ans ✅-Extreme diet, fasting, excessive exercise
Anorexia Nervosa
Subtype Binge/Purge Type - Ans ✅-Self-induced vomiting, laxative abuse, diuretic
abuse, enemas
(Significantly low body weight/Low BMI)
Differentiating Anorexia Nervosa Binge/Purge Type from Bulimia Nervosa - Ans ✅-
Anorexia nervosa has significantly low body weight / low BMI
Anorexia Nervosa
Severity Based on BMI - Ans ✅-Mild: > 17
Moderate: 16-16.99
Severe: 15-15.99
,NURS 663 EXAM 2
Extreme: < 15
Anorexia Nervosa
Treatment - Ans ✅-- Behavioral, interpersonal, cognitive, and family therapies
- Assessments both psychological and physical
- Psychological and behavioral interventions are key
- Nutritional interventions are required
Pharmacological interventions have limited role with the exception of treating co-
morbidities (MDD, GAD)
Anorexia Nervosa
Conclusion - Ans ✅-- Least prevalent, the most obvious due to obvious low weight
- No FDA medication, treat co-occurring mood disorders (MDD, GAD with SSRI)
Bulimia Nervosa
"Bulimics Over-Consume Pasteries" - Ans ✅-B: recurrent Binge episodes (1x/wk x 3
months)
O: Out of control overeating
C: excessive Concern with body shape/weight
P: Purging or other compensatory behaviors
Bulimia Nervosa
Severity Based on # of Episodes/week - Ans ✅-Mild: 1-3/wk
Moderate: 4-7/wk
Severe: 8-13/wk
Extreme: 14+/wk
,NURS 663 EXAM 2
Bulimia Nervosa
Pharmacological Interventions - Ans ✅-fluoxetine (Prozac) only FDA-approved, higher
dose used than for MDD
Bulimia Nervosa
Conclusion - Ans ✅-- Second most-prevalent, easier to hide
- fluoxetine (Prozac) FDA-approved, treat co-occurring disorders if needed (mood
stabilizer for MDD treatment-resistant)
Binge Eating Disorder
"Binge-Eaters Overeat" - Ans ✅-B: recurrent Binge episodes (1x/wk x 3 months)
O: Out of control overeating
Plus 3 or more of the following:
1. Eat fast past full
2. Feast when not famished
3. Flushed and flustered and feeling disgusted
Binge-Eating Disorder - Ans ✅-- A sense of lack of control overeating during the
episode
- Occurring AT LEAST 1x per week for 3 MONTHS
- Associated with marked distress
Binge Episodes are Associated with ≥ 3 of the Following: - Ans ✅-- Eating more rapidly
than usual
- Eating until feeling uncomfortably full
- Eating large amounts of food when not feeling physically hungry
- Eating alone because of feeling embarrassed by how much one is eating
, NURS 663 EXAM 2
- Feeling disgusted with oneself, depressed or guilty afterwards
(Common for all 5 to be present)
Binge-Eating Disorder
Severity Based on # of Episodes/week - Ans ✅-Mild: 1-3/wk
Moderate: 4-7/wk
Severe: 8-13/wk
Extreme: 14+/wk
Binge Eating Disorder
Pharmacological Interventions - Ans ✅-lisdexamfetamine (Vyvanse): Currently the only
FDA approved medication
Topiramate: Causes cognitive dysfunction when dosed for effectiveness
Anti-obesity agents target appetite and weight, but no the behavior
Naltrexone: "Hit or miss," results
Baclofen: Some evidence it reduces automatic behaviors, it can take high doses; do not
abruptly disrupt due to possible psychosis
Dasotraline: In phase 3 for BED and dual-acting DA and NE reuptake inhibitor, shows
promise, not on the market yet
Binge-Eating Disorder
Conclusion - Ans ✅-- Most prevalent, often not screened for
- Known as a "shameful secret"
- lisdexamefetamine (Vyvanse) only FDA-approved medication
Bulimia Nervosa and BED
NURS 663 EXAM 2 Questions and
Answers 2025
Anorexia Nervosa
"RID" - Ans ✅-R: Restriction of intake leading to significantly low body weight
I: Intense fear of weight gain
D: Disturbance in perception of one's weight or body image
When Anorexia Nervosa is Diagnosed - Ans ✅-When a person's weighs at least 15%
less than their normal/idea body weight
Anorexia Nervosa
Subtype Restricting Type - Ans ✅-Extreme diet, fasting, excessive exercise
Anorexia Nervosa
Subtype Binge/Purge Type - Ans ✅-Self-induced vomiting, laxative abuse, diuretic
abuse, enemas
(Significantly low body weight/Low BMI)
Differentiating Anorexia Nervosa Binge/Purge Type from Bulimia Nervosa - Ans ✅-
Anorexia nervosa has significantly low body weight / low BMI
Anorexia Nervosa
Severity Based on BMI - Ans ✅-Mild: > 17
Moderate: 16-16.99
Severe: 15-15.99
,NURS 663 EXAM 2
Extreme: < 15
Anorexia Nervosa
Treatment - Ans ✅-- Behavioral, interpersonal, cognitive, and family therapies
- Assessments both psychological and physical
- Psychological and behavioral interventions are key
- Nutritional interventions are required
Pharmacological interventions have limited role with the exception of treating co-
morbidities (MDD, GAD)
Anorexia Nervosa
Conclusion - Ans ✅-- Least prevalent, the most obvious due to obvious low weight
- No FDA medication, treat co-occurring mood disorders (MDD, GAD with SSRI)
Bulimia Nervosa
"Bulimics Over-Consume Pasteries" - Ans ✅-B: recurrent Binge episodes (1x/wk x 3
months)
O: Out of control overeating
C: excessive Concern with body shape/weight
P: Purging or other compensatory behaviors
Bulimia Nervosa
Severity Based on # of Episodes/week - Ans ✅-Mild: 1-3/wk
Moderate: 4-7/wk
Severe: 8-13/wk
Extreme: 14+/wk
,NURS 663 EXAM 2
Bulimia Nervosa
Pharmacological Interventions - Ans ✅-fluoxetine (Prozac) only FDA-approved, higher
dose used than for MDD
Bulimia Nervosa
Conclusion - Ans ✅-- Second most-prevalent, easier to hide
- fluoxetine (Prozac) FDA-approved, treat co-occurring disorders if needed (mood
stabilizer for MDD treatment-resistant)
Binge Eating Disorder
"Binge-Eaters Overeat" - Ans ✅-B: recurrent Binge episodes (1x/wk x 3 months)
O: Out of control overeating
Plus 3 or more of the following:
1. Eat fast past full
2. Feast when not famished
3. Flushed and flustered and feeling disgusted
Binge-Eating Disorder - Ans ✅-- A sense of lack of control overeating during the
episode
- Occurring AT LEAST 1x per week for 3 MONTHS
- Associated with marked distress
Binge Episodes are Associated with ≥ 3 of the Following: - Ans ✅-- Eating more rapidly
than usual
- Eating until feeling uncomfortably full
- Eating large amounts of food when not feeling physically hungry
- Eating alone because of feeling embarrassed by how much one is eating
, NURS 663 EXAM 2
- Feeling disgusted with oneself, depressed or guilty afterwards
(Common for all 5 to be present)
Binge-Eating Disorder
Severity Based on # of Episodes/week - Ans ✅-Mild: 1-3/wk
Moderate: 4-7/wk
Severe: 8-13/wk
Extreme: 14+/wk
Binge Eating Disorder
Pharmacological Interventions - Ans ✅-lisdexamfetamine (Vyvanse): Currently the only
FDA approved medication
Topiramate: Causes cognitive dysfunction when dosed for effectiveness
Anti-obesity agents target appetite and weight, but no the behavior
Naltrexone: "Hit or miss," results
Baclofen: Some evidence it reduces automatic behaviors, it can take high doses; do not
abruptly disrupt due to possible psychosis
Dasotraline: In phase 3 for BED and dual-acting DA and NE reuptake inhibitor, shows
promise, not on the market yet
Binge-Eating Disorder
Conclusion - Ans ✅-- Most prevalent, often not screened for
- Known as a "shameful secret"
- lisdexamefetamine (Vyvanse) only FDA-approved medication
Bulimia Nervosa and BED
